AGM/EGMMay 5, 2026, 07:23 AM
FibroBiologics Sets Annual Meeting, Proposes Stock Issuance, Equity Plan
AI Summary
FibroBiologics, Inc. announced its Annual Meeting of Stockholders will be held virtually on June 22, 2026. Stockholders will vote on the election of Pete O’Heeron as a Class III director, the ratification of WithumSmith+Brown, PC as the independent auditor, and the approval of a stock issuance of up to 2,272,728 common shares from the March SPA and 159,091 shares from the Engagement Letter. Additionally, approval for the 2026 Equity and Incentive Compensation Plan will be sought. Pete O’Heeron's Series C Preferred Stock, subject to an irrevocable proxy to the Board, accounts for 1,625,000 votes, or approximately 24% of the total votes.
Key Highlights
- Annual Meeting of Stockholders scheduled for June 22, 2026, to be held virtually.
- Stockholders to vote on the election of Pete O’Heeron as a Class III director.
- Stacy Coen, a current Class III director, will not be standing for re-election.
- Proposal to ratify WithumSmith+Brown, PC as the independent auditor for 2026.
- Approval sought for issuance of up to 2,272,728 common shares from March SPA and 159,091 shares from Engagement Letter.
- Approval sought for the FibroBiologics, Inc. 2026 Equity and Incentive Compensation Plan.
- CEO Pete O’Heeron's Series C Preferred Stock holds 1,625,000 votes, representing 24% of total votes.
Price Impact
More from FBLG